“COMPARISON OF THE EFFECT OF SILDENAFIL AND TADALAFIL ON PULMONARY HYPERTENSION ASSOCIATED WITH HEMODYNAMICALLY SIGNIFICANT PDAS TREATMENT OF PULMONARY HYPERTENSION IN HS-PDA PATIENTS”, Journal of Pharmaceutical Negative Results, pp. 3266–3274, Dec. 2022, doi: 10.47750/pnr.2022.13.S08.401.